The FDA has accepted the resubmission of the BLA of Ordspono for review in relapsed/refractory follicular lymphoma following previous systemic therapy.

Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in ...

Antengene’s new drug application (NDA) for Xpovio (selinexor) has gained approval from the Indonesia National Agency of Drug ...

Antengene’s Xpovio approved for commercialization in Indonesia: Shanghai Thursday, March 6, 2025, 12:00 Hrs [IST] Antengene Corporation Limited, a leading innovative, commercial ...

Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from manageable conditions to fatal diseases.

Kymriah was cleared by the FDA for the follicular lymphoma use last year as well, a little after Yescarta, adding to its earlier approvals for diffuse large B-cell lymphoma (DLBCL) and acute ...

He was diagnosed with two types of lymphoma cancer — follicular lymphoma, an incurable cancer, and large B cell lymphoma, ...

Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from ...

No one should have to choose between paying for prescription drugs and putting food on the table. That's why the Government of Canada is taking action so Canadians can get the medication they need, ...

"New therapeutic options are needed for follicular lymphoma ... impressive results in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) at this year's ASCO congress.

The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for obinutuzumab (Gazyva®) for the treatment of ...